Alpha Tau Medical Ltd

NASDAQ DRTS

Data sourced from

and

Download Data

Alpha Tau Medical Ltd EBIT to Total Assets Ratio 5 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: -19.68%

Alpha Tau Medical Ltd EBIT to Total Assets Ratio 5 year CAGR is -19.68% for the Trailing 12 Months (TTM) ending March 31, 2024. The EBIT to Total Assets Ratio measures a company's operating earnings (EBIT) generated per dollar of total assets. It shows how efficiently a company utilizes its assets to generate earnings. A higher ratio indicates better asset utilization and profitability. It reflects the ability of a company to generate earnings from its invested assets and is useful in assessing operational efficiency and financial performance. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Alpha Tau Medical Ltd EBIT to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was -0.10, a 43.24% change year over year.
Alpha Tau Medical Ltd EBIT to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was -0.17, a -6.67% change year over year.
Alpha Tau Medical Ltd EBIT to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was -0.16, a 30.37% change year over year.
Alpha Tau Medical Ltd EBIT to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was -0.23, a 7.82% change year over year.

NASDAQ: DRTS

Alpha Tau Medical Ltd

CEO	Mr. Uzi Sofer
IPO Date	March 8, 2021
Location	Israel
Headquarters	5 Kiryat Hamada Street, Jerusalem, Israel, 9777605
Employees	121
Sector	Healthcare
Industry	Biotechnology

Description

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Key trends